Agios Pharmaceuticals Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 3/6

Agios Pharmaceuticals yıllık ortalama 19.3% oranında kazançlarını artırırken, Biotechs sektöründe kazançlar growing at 13.2% annual. Gelirler declining yılda ortalama 22.3% oranında artmaktadır. Agios Pharmaceuticals'in özkaynak karlılığı 41.5% ve net marjı 2051.4%'dir.

Anahtar bilgiler

19.3%

Kazanç büyüme oranı

16.6%

EPS büyüme oranı

Biotechs Sektör Büyümesi	12.9%
Gelir büyüme oranı	-22.3%
Özkaynak getirisi	41.5%
Net Marj	2,051.4%
Son Kazanç Güncellemesi	30 Sep 2024

Yakın geçmiş performans güncellemeleri

Recent updates

Gelir ve Gider Dağılımı

Agios Pharmaceuticals nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

BMV:AGIO * Gelir, gider ve kazançlar (USD Millions )
Tarih	Gelir	Kazançlar	G+A Giderleri	Ar-Ge Giderleri
30 Sep 24	33	674	140	0
30 Jun 24	31	-365	128	0
31 Mar 24	29	-353	123	0
31 Dec 23	27	-352	120	0
30 Sep 23	24	-220	117	0
30 Jun 23	20	-210	121	0
31 Mar 23	19	-218	119	0
31 Dec 22	14	-232	122	0
30 Sep 22	10	-367	120	0
30 Jun 22	6	-369	118	0
31 Mar 22	1	-360	119	0
31 Dec 21	0	-357	121	0
30 Sep 21	0	-342	116	221
30 Jun 21	0	-337	117	221
31 Mar 21	0	-336	117	221
31 Dec 20	0	-329	115	0
30 Sep 20	35	-347	124	0
30 Jun 20	61	-374	129	0
31 Mar 20	88	-402	132	0
31 Dec 19	0	-301	102	214
30 Sep 19	112	-401	129	0
30 Jun 19	102	-389	127	0
31 Mar 19	116	-348	121	0
31 Dec 18	94	-346	114	0
30 Sep 18	74	-343	105	0
30 Jun 18	70	-325	91	0
31 Mar 18	41	-339	81	0
31 Dec 17	43	-315	71	0
30 Sep 17	56	-283	64	0
30 Jun 17	53	-269	58	0
31 Mar 17	49	-241	55	0
31 Dec 16	70	-198	51	0
30 Sep 16	53	-183	46	0
30 Jun 16	50	-160	44	0
31 Mar 16	56	-136	40	0
31 Dec 15	59	-118	36	0
30 Sep 15	68	-104	32	0
30 Jun 15	96	-60	28	0
31 Mar 15	91	-46	23	0
31 Dec 14	65	-54	19	0
30 Sep 14	57	-39	16	0
30 Jun 14	30	-55	14	0
31 Mar 14	28	-47	11	0
31 Dec 13	26	-44	10	0

Kaliteli Kazançlar: AGIO * yüksek düzeyde nakit dışı kazança sahiptir.

Büyüyen Kar Marjı: AGIO * geçmişte karlı hale geldi.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: AGIO * son 5 yılda karlı hale geldi ve kazançlarını yıllık 19.3% oranında artırdı.

Büyüme Hızlandırma: AGIO * son bir yılda karlı hale geldi, bu da kazanç büyüme oranının 5 yıllık ortalamayla karşılaştırılmasını zorlaştırıyor.

Kazançlar vs. Sektör: AGIO * son bir yılda karlı hale geldi ve bu durum, geçmiş yıl kazanç büyümesinin Biotechs sektörüyle ( 4% ) karşılaştırılmasını zorlaştırıyor.

Özkaynak Getirisi

Yüksek ROE: AGIO * 'nin Özsermaye Getirisi ( 41.5% ) ödenmemiş olarak değerlendirilmektedir.

Agios Pharmaceuticals Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 3/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

Agios Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 01, 2024

Agios Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 15, 2024

Agios Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Agios Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Agios Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 05, 2022

Third quarter 2020 earnings released: US$1.43 loss per share

Recent updates

Agios Pharmaceuticals, Inc. Completes Enrollment of Phase 3 RISE UP Study of Mitapivat in Sickle Cell Disease

Agios to Receive $1.1 Billion in Milestone Payments Following FDA Approval of Vorasidenib

Agios Pharmaceuticals, Inc. Announces Results from Phase 3 ACTIVATE-KidsT Study of Mitapivat in Children with PK Deficiency Who Are Regularly Transfused

Agios Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 01, 2024

Agios Pharmaceuticals, Inc. Presents Positive Results from Phase 3 ENERGIZE Study of Mitapivat in Non-Transfusion-Dependent Thalassemia in Plenary Session at the European Hematology Association 2024 Hybrid Congress

Agios Pharmaceuticals, Inc. Announces Phase 3 Energize-T Study of Mitapivat Met Primary Endpoint and All Key Secondary Endpoints in Adults with Transfusion-Dependent Alpha- or Beta-Thalassemia

Agios Pharmaceuticals, Inc., Annual General Meeting, Jun 20, 2024

Agios Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 15, 2024

Agios Pharmaceuticals, Inc. Announces Key Anticipated 2024 Milestones Across Rare Disease Portfolio

Agios Pharmaceuticals, Inc. Presents Positive Results from Phase 2 Portion of the Rise Up Pivotal Study in Sickle Cell Disease at 65Th ASH Annual Meeting and Exposition

Agios Pharmaceuticals, Inc. Announces Clinical Proof-Of-Concept in Phase 2A Trial of AG-946 for the Treatment of Anemia in Lower-Risk Myelodysplastic Syndromes

Agios Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Agios Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Agios Pharmaceuticals, Inc. Announces Board Changes

Agios Pharmaceuticals, Inc. Presents Updated PYRUKYND® (mitapivat) Long-term Extension Data Demonstrating Sustained Clinical Benefits in Adults with Pyruvate Kinase (PK) Deficiency at 64th ASH Annual Meeting and Exposition

Agios Pharmaceuticals, Inc. Appoints Tsveta Milanova as Chief Commercial Officer, Effective Jan. 3, 2023

Agios Pharmaceutical's PYRUKYND® Approves in the EU for the Treatment of Pyruvate Kinase (PK) Deficiency in Adult Patients

Agios Pharmaceuticals, Inc. Appoints Cecilia Jones as Chief Financial Officer, Effective September 26, 2022

Agios Pharmaceuticals, Inc. Receives Positive Chmp Opinion for Pyrukynd® (Mitapivat) for the Treatment of Pyruvate Kinase (Pk) Deficiency in Adult Patients

Agios Pharmaceuticals, Inc. Announces Resignation of Jonathan Biller as Chief Financial Officer, Effective September 16, 2022

Agios Pharmaceuticals, Inc. Appoints Rahul Ballal and Cynthia Smith to Board of Directors

Agios Pharmaceuticals, Inc. Announces Publication of Phase 2 Data in The Lancet Demonstrating Safety and Efficacy of PYRUKYND® (mitapivat) in Non-transfusion-dependent a- and ß-Thalassemia

Insufficient new directors

Agios Pharmaceuticals, Inc. Announces Management Changes, Effective August 8, 2022

Insufficient new directors

Agios Presents New Clinical Data Supporting the Benefits of Pyrukynd® Treatment in Adults with PK Deficiency At European Hematology Association Annual Congress

Agios Pharmaceuticals, Inc. Announces Resignation of Bruce Car as Chief Scientific Officer, effective as of August 1, 2022

Agios Pharmaceuticals, Inc. Announces Management Changes

Agios Pharmaceuticals, Inc. Announces Executive Changes

Agios Pharmaceuticals, Inc. Announces Resignation of Ian T. Clark from the Board

Agios Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 05, 2022

Insufficient new directors

Agios Pharmaceuticals, Inc. Announces FDA Approval of Pyrukynd (Mitapivat) as First Disease-Modifying Therapy for Hemolytic Anemia in Adults with Pyruvate Kinase Deficiency

No longer forecast to breakeven

Insufficient new directors

No longer forecast to breakeven

Agios Pharmaceuticals, Inc. Presents Mitapivat Long-term Extension Data Demonstrating Durability of Hemoglobin Response and Transfusion Burden Reduction in Adults with Pyruvate Kinase (PK) Deficiency at 63rd ASH Annual Meeting and Exposition

Chief Commercial Officer Darrin Miles has left the company

Insufficient new directors

Forecast to breakeven in 2021

Forecast to breakeven in 2021

Agios Pharmaceuticals, Inc. Announces FDA Acceptance and Priority Review of New Drug Application for Mitapivat for Treatment of Adults with Pyruvate Kinase Deficiency

Principal Accounting Officer and VP of Accounting, Treasury & Tax Carman Alenson has left the company

Agios Pharmaceuticals, Inc.(NasdaqGS:AGIO) dropped from Russell Midcap Value Index

Agios Pharmaceuticals, Inc. Submits New Drug Application to FDA for Mitapivat for Treatment of Adults with Pyruvate Kinase Deficiency

Agios Pharmaceuticals, Inc. Presents Positive Results from Phase 2 Study of Mitapivat in Non-Transfusion-Dependent a- and ß-Thalassemia at the European Hematology Association Virtual Congress

Agios Reports Clinical Data Presentations

Agios Pharmaceuticals, Inc. Announces Closing of Oncology Business Sale to Servier

Agios Submits Supplemental New Drug Application to FDA for TIBSOVO® (ivosidenib tablets) for Patients with Previously Treated IDH1-Mutant Cholangiocarcinoma

Agios Pharmaceuticals, Inc. Announces the Appointment of Darrin Miles to Role of Chief Commercial Officer

Agios Announces Phase 3 ACTIVATE-T Trial of Mitapivat Achieved Primary Endpoint in Adults with Pyruvate Kinase Deficiency Who Are Regularly Transfused

Agios Presents Final Data from Phase 3 ClarIDHy Study of TIBSOVO® (ivosidenib tablets) in Patients with Previously Treated IDH1-Mutant Cholangiocarcinoma

Servier Pharmaceuticals, LLC entered into a definitive agreement to acquire oncology business from Agios Pharmaceuticals, Inc. (NasdaqGS:AGIO) for $2 billion.

Agios Pharmaceuticals, Inc. Announces the Phase 3 ACTIVATE Trial of Mitapivat Achieved its Primary Endpoint in Adults with Pyruvate Kinase Deficiency Who Are Not Regularly Transfused

Agios Pharmaceuticals, Inc. Launches Anemia ID

Agios Announces FDA Orphan Drug Designation Granted to Mitapivat for Treatment of Sickle Cell Disease

Third quarter 2020 earnings released: US$1.43 loss per share

Revenue misses expectations

Agios Announces Withdrawal of European Marketing Authorization Application for TIBSOVO as a Treatment for Relapsed or Refractory IDH1-mutant Acute Myeloid Leukemia

Agios Pharmaceuticals, Inc. Announces Final Overall Survival Data from Phase 3 ClarIDHy Study of TIBSOVO

Gelir ve Gider Dağılımı

Kazanç ve Gelir Geçmişi

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Özkaynak Getirisi

Varlık Getirisi

Kullanılan Sermaye Getirisi

Geçmişte güçlü performans gösteren şirketleri keşfedin